CN102293770A — 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂
Assigned to Wenzhou Medical College · Expires 2011-12-28 · 14y expired
What this patent protects
本发明属医药技术领域,具体涉及以下11个化合物在制备成纤维细胞生长因子受体(FGFR)酪氨酸激酶抑制剂药物中的应用:3,5-二(2,4-二氯苯亚甲基)哌啶-4-酮;3,5-二(2-氯苯亚甲基)哌啶-4-酮;3,5-二(2-溴苯亚甲基)哌啶-4-酮;3,5-二(3,4-二氟苯亚甲基)哌啶-4-酮;3,5-二(3-氟苯亚甲基)哌啶-4-酮;3,5-二(3,4-二羟基苯亚甲基)哌啶-4-酮;3,5-二(3,4-二羟基苯亚甲基)-1-甲基哌啶-4-酮;3,5-二(3,4-二羟基苯亚甲基)-四氢吡喃-4-酮;3,5-二(3,4-二羟基苯亚甲基)-四氢噻喃-4-酮;…
USPTO Abstract
本发明属医药技术领域,具体涉及以下11个化合物在制备成纤维细胞生长因子受体(FGFR)酪氨酸激酶抑制剂药物中的应用:3,5-二(2,4-二氯苯亚甲基)哌啶-4-酮;3,5-二(2-氯苯亚甲基)哌啶-4-酮;3,5-二(2-溴苯亚甲基)哌啶-4-酮;3,5-二(3,4-二氟苯亚甲基)哌啶-4-酮;3,5-二(3-氟苯亚甲基)哌啶-4-酮;3,5-二(3,4-二羟基苯亚甲基)哌啶-4-酮;3,5-二(3,4-二羟基苯亚甲基)-1-甲基哌啶-4-酮;3,5-二(3,4-二羟基苯亚甲基)-四氢吡喃-4-酮;3,5-二(3,4-二羟基苯亚甲基)-四氢噻喃-4-酮;3,5-二(3,4-二氟苯亚甲基)-四氢吡喃-4-酮;3,5-二(双(2-氯乙基)氨基苯亚甲基)-四氢噻喃-4-酮。
Drugs covered by this patent
- Balversa (ERDAFITINIB) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.